Exploring the Experience of Black Americans Living with Hidradenitis Suppurativa in the United States Healthcare System: A Narrative Review.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-10-01 Epub Date: 2025-07-25 DOI:10.1007/s13555-025-01496-x

Nicole A Negbenebor, Julia M Riley

{"title":"Exploring the Experience of Black Americans Living with Hidradenitis Suppurativa in the United States Healthcare System: A Narrative Review.","authors":"Nicole A Negbenebor, Julia M Riley","doi":"10.1007/s13555-025-01496-x","DOIUrl":null,"url":null,"abstract":"<p><p>Black Americans face persistent healthcare disparities due to a combination of structural, socioeconomic, and historical factors, which can lead to disparities in healthcare quality access and health outcomes. Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is associated with high physical, socioeconomic, and emotional burdens. HS is an example of the broader heath disparities faced by Black patients in the USA. The overall prevalence of HS in the USA is estimated to be 0.1-1.7%, but the prevalence is more than threefold higher among Black individuals than among White individuals. Black patients with HS often have more severe disease than White patients but face longer diagnostic delays and have less access to specialized dermatologic care. By addressing the barriers to care faced by Black patients with HS, dermatologists and healthcare providers can reduce health disparities and improve outcomes for these patients. The objective of this clinical review is to provide an overview of the disparities in clinical burden, diagnostic delays, and treatment faced by Black patients with HS. We also provide commentary from the physician's perspective on factors that contribute to these health disparities and approaches to reduce barriers to appropriate HS care.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2715-2727"},"PeriodicalIF":4.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454235/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01496-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Black Americans face persistent healthcare disparities due to a combination of structural, socioeconomic, and historical factors, which can lead to disparities in healthcare quality access and health outcomes. Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is associated with high physical, socioeconomic, and emotional burdens. HS is an example of the broader heath disparities faced by Black patients in the USA. The overall prevalence of HS in the USA is estimated to be 0.1-1.7%, but the prevalence is more than threefold higher among Black individuals than among White individuals. Black patients with HS often have more severe disease than White patients but face longer diagnostic delays and have less access to specialized dermatologic care. By addressing the barriers to care faced by Black patients with HS, dermatologists and healthcare providers can reduce health disparities and improve outcomes for these patients. The objective of this clinical review is to provide an overview of the disparities in clinical burden, diagnostic delays, and treatment faced by Black patients with HS. We also provide commentary from the physician's perspective on factors that contribute to these health disparities and approaches to reduce barriers to appropriate HS care.

查看原文本刊更多论文

探索美国医疗保健系统中患有化脓性汗腺炎的美国黑人的经历：叙述回顾。

由于结构性、社会经济和历史因素的结合，美国黑人面临着持续的医疗保健差距，这可能导致医疗保健质量和健康结果的差异。化脓性汗腺炎（HS）是一种慢性炎症性疾病，与高身体、社会经济和情感负担有关。HS是美国黑人患者面临的更广泛的健康差异的一个例子。据估计，HS在美国的总体患病率为0.1-1.7%，但黑人的患病率是白人的三倍多。患有HS的黑人患者通常比白人患者病情更严重，但面临更长的诊断延误，并且很少有机会获得专门的皮肤科护理。通过解决黑人HS患者面临的护理障碍，皮肤科医生和医疗保健提供者可以减少健康差距并改善这些患者的结果。本临床综述的目的是概述黑人HS患者在临床负担、诊断延误和治疗方面的差异。我们还从医生的角度对导致这些健康差异的因素和减少适当卫生保健障碍的方法进行了评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.